ClariVest Asset Management’s Pacific Biosciences PACB Stock Holding History

ClariVest Asset Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-80,304	Closed	-$1.64M	–	768
2021 Q4	$1.64M	Sell	80,304 -7,238	-8%	-$175K	0.05%	257
2021 Q3	$2.24M	Sell	87,542 -22,281	-20%	-$660K	0.07%	225
2021 Q2	$3.84M	Sell	109,823 -212	-0.2%	-$6.17K	0.13%	157
2021 Q1	$3.67M	Buy	+110,035	New	+$3.85M	0.13%	150

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClariVest Asset Management's PACB Position: Q1 2022 in Review

ClariVest Asset Management sold out of Pacific Biosciences (PACB) in Q1 2022, closing a stake of 80,304 shares — an estimated $1.64M sold.

ClariVest Asset Management first reported a position in PACB in Q1 2021 and held it in 4 quarters. The position peaked at $3.84M in Q2 2021. 250 funds tracked by Wall St. Rank hold PACB as of Q1 2022.

ClariVest Asset Management reported no remaining Pacific Biosciences position as of Q1 2022 after selling out during the quarter.
ClariVest Asset Management sold 80,304 Pacific Biosciences shares in Q1 2022, an estimated $1.64M.
ClariVest Asset Management first reported a position in Pacific Biosciences in Q1 2021 and held it in 4 quarters.
ClariVest Asset Management's Pacific Biosciences position peaked at $3.84M in Q2 2021.
250 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2022.

Based on ClariVest Asset Management's 13F filing for Q1 2022, filed 4 May 2022.